Sound Bioventures
DenmarkKey facts
Recent exits
No exits recorded yet.
Coverage notes
0 funds tracked, 0 portfolio companies (0 active · 0 realized). Verified weekly from public filings and deal announcements.
About Sound Bioventures
Sound Bioventures is a specialist late-preclinical and clinical-stage biotech investor with €116 million of assets under management as of December 2024 (Fund I final close with Novo Holdings as anchor LP), headquartered in Copenhagen with Malmö Sweden plus US presence. The firm was founded in 2020 and operates as a partner-owned independent VC firm with transatlantic syndicate access and Novo Holdings backing.
Investment thesis
Sound Bioventures deploys capital through Sound Bioventures Fund I targeting about-to-be-clinical and clinical-stage private biotech investing in specialty therapeutics, orphan and rare diseases. The platform follows a cross-Atlantic Europe-US strategy with sector focus across biotechnology, therapeutics, oncology, rare diseases, ophthalmology, cardiology and immunology. Geographic deployment spans Europe (Nordic core) and the United States, with transatlantic syndicate co-investment access.
Recent activity
As Fund I is in active deployment phase (2020 vintage), realised exits have not been reported 2024-2026. Recent investments include Cytospire Therapeutics Series A (oncology, 2026), Aboleris Pharma (immunology, 2024-2025), Arthex (biotech, 2024-2025) and Teitur Trophics (therapeutics, 2024-2025). The platform continues active deployment of Fund I across the transatlantic life sciences franchise. Detailed buyer names and multiple data available on Pro at €49/month.
Similar firms
Other private equity firms tracked on GP Intel.
See the full fund history.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in